EKF Diagnostics to Showcase New Handheld β-ketone & Glucose Analyzer at AACC 2021

EKF Diagnostics, the global in vitro diagnostics company, announces that it will be demonstrating its new STAT-Site® WB dual analyte measurement system at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

As EKF’s first face-to-face event since COVID-19 restrictions began, this will be the premiere of the new handheld analyzer for reliable and efficient β-ketone and glucose measurement from whole blood in seconds. Visitors will be able to see firsthand how easy it is to use the CLIA waived and CE marked device in professional settings to monitor the effectiveness of diabetes control programs. EKF will also be introducing its newest hemoglobin analyzer for the US market, the Hemo Control, which provides near patient hemoglobin and hematocrit results in one test as quickly as 25 seconds.

EKF’s team of point-of-care and central laboratory diagnostics experts at the Georgia World Congress Center in Atlanta, U.S., September 26-30, will also highlight the Lucica® Glycated Albumin-L. Manufactured by Asahi Kasei Pharma, it is a specific test for glycated albumin (“GA”) and is FDA cleared for sale in the U.S. where it is sold exclusively by EKF Diagnostics. This established test enables intermediate term glycemic monitoring of diabetics over the preceding 2-3 weeks.

The Lucica® Glycated Albumin-L is a quantitative, enzymatic test for use on compatible clinical chemistry analyzers as a “user defined” method. The Lucica® method has appeared in numerous published studies.

Glycated Albumin levels are not affected by the life span of red blood cells (“RBC”), and therefore it is a useful substitute when the HbA1c interpretation is problematic such as in the presence of hemoglobinopathies, iron deficiency, and anemias. Another key feature of glycated albumin is that it changes more rapidly and markedly than HbA1c. Therefore, GA is a good marker to monitor the effects of changes in therapy in patients with diabetes when more rapid treatment responses are needed.

The STAT-Site® WB and Lucica® Glycated Albumin-L test are part of a suite of other diabetes care products that EKF will be showcasing at 2021 AACC. These include its Beta-Hydroxybutyrate LiquiColor® Assay (B-HB) and Nitro-Tab Ketone Tablets, both of which provide quick and simple tests for ketosis.

Other product highlights on EKF’s stand for point-of-care and central laboratory testing include its hemoglobin analyzers, the hand-held DiaSpect Tm and the HemoPoint® H2 which offers both hemoglobin and hematocrit results in one test within 30-60 seconds. Additional analyzers on show include the Biosen RUO glucose and lactate analyzer.

EKF will also discuss its growing EKF Life Sciences business which provides contract manufacturing services, as well as manufacturing diagnostic enzymes for use in medical diagnostics, pharmaceuticals and industry. This follows recent significant investment in its longstanding fermentation facility in Elkhart, Indiana, where it has been manufacturing enzymes and related biomolecules from bacterial fermentation since 1983.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution